Owlstone Medical has won a contract from the US Department of Defense that will allow it to develop a handheld breath biopsy device for early infectious diseases.
FDA approves the third anti-TB drug in more than 40 years after the compound showed significantly higher success rates in patients with multi drug-resistant and extensively drug-resistant TB.
Meridian Clinical Research acquires Regional Clinical Research in a deal that will see its North American footprint expand to more than 20 investigative clinical trial sites.
NC-based FHI Clinical last week officially launched as a new full-service contract research organization with a global team the “right size” to adjust when needed, says CEO.